Editor's Choice- Impact of identifying precipitating factors on 30-day mortality in acute heart failure patients.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
Oct 2019
Historique:
pubmed: 23 8 2019
medline: 11 2 2020
entrez: 23 8 2019
Statut: ppublish

Résumé

The aim of this study was to describe the prevalence and prognostic value of the most common triggering factors in acute heart failure. Patients with acute heart failure from 41 Spanish emergency departments were recruited consecutively in three time periods between 2011 and 2016. Precipitating factors were classified as: (a) unrecognized; (b) infection; (c) atrial fibrillation; (d) anaemia; (e) hypertension; (f) acute coronary syndrome; (g) non-adherence; and (h) two or more precipitant factors. Unadjusted and adjusted logistic regression models were used to assess the association between 30-day mortality and each precipitant factor. The risk of dying was further evaluated by week intervals over the 30-day follow-up to assess the period of higher vulnerability for each precipitant factor. Approximately 69% of our 9999 patients presented with a triggering factor and 1002 died within the first 30 days (10.0%). The most prevalent factors were infection and atrial fibrillation. After adjusting for 11 known predictors, acute coronary syndrome was associated with higher 30-day mortality (odds ratio (OR) 1.87; 95% confidence interval (CI) 1.02-3.42), whereas atrial fibrillation (OR 0.75; 95% CI 0.56-0.94) and hypertension (OR 0.34; 95% CI 0.21-0.55) were significantly associated with better outcomes when compared to patients without precipitant. Patients with infection, anaemia and non-compliance were not at higher risk of dying within 30 days. These findings were consistent across gender and age groups. The 30-day mortality time pattern varied between and within precipitant factors. Precipitant factors in acute heart failure patients are prevalent and have a prognostic value regardless of the patient's gender and age. They can be managed with specific treatments and can sometimes be prevented.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to describe the prevalence and prognostic value of the most common triggering factors in acute heart failure.
METHODS METHODS
Patients with acute heart failure from 41 Spanish emergency departments were recruited consecutively in three time periods between 2011 and 2016. Precipitating factors were classified as: (a) unrecognized; (b) infection; (c) atrial fibrillation; (d) anaemia; (e) hypertension; (f) acute coronary syndrome; (g) non-adherence; and (h) two or more precipitant factors. Unadjusted and adjusted logistic regression models were used to assess the association between 30-day mortality and each precipitant factor. The risk of dying was further evaluated by week intervals over the 30-day follow-up to assess the period of higher vulnerability for each precipitant factor.
RESULTS RESULTS
Approximately 69% of our 9999 patients presented with a triggering factor and 1002 died within the first 30 days (10.0%). The most prevalent factors were infection and atrial fibrillation. After adjusting for 11 known predictors, acute coronary syndrome was associated with higher 30-day mortality (odds ratio (OR) 1.87; 95% confidence interval (CI) 1.02-3.42), whereas atrial fibrillation (OR 0.75; 95% CI 0.56-0.94) and hypertension (OR 0.34; 95% CI 0.21-0.55) were significantly associated with better outcomes when compared to patients without precipitant. Patients with infection, anaemia and non-compliance were not at higher risk of dying within 30 days. These findings were consistent across gender and age groups. The 30-day mortality time pattern varied between and within precipitant factors.
CONCLUSIONS CONCLUSIONS
Precipitant factors in acute heart failure patients are prevalent and have a prognostic value regardless of the patient's gender and age. They can be managed with specific treatments and can sometimes be prevented.

Identifiants

pubmed: 31436133
doi: 10.1177/2048872619869328
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-680

Investigateurs

Marta Fuentes (M)
Cristina Gil (C)
Héctor Alonso (H)
Enrique Pérez-Llantada (E)
Francisco Javier Martín-Sánchez (FJ)
Guillermo Llopis García (GL)
Mar Suárez Cadenas (MS)
Òscar Miró (Ò)
Víctor Gil (V)
Rosa Escoda (R)
Carolina Xipell (C)
Carolina Sánchez (C)
María José Pérez-Durá (MJ)
Eva Salvo (E)
José Pavón (J)
Antonio Noval (A)
José Manuel Torres (JM)
María Luisa López-Grima (ML)
Amparo Valero (A)
María Ángeles Juan (MÁ)
Alfons Aguirre (A)
Maria Àngels Pedragosa (MÀ)
Silvia Mínguez Masó (SM)
María Isabel Alonso (MI)
Francisco Ruiz (F)
José Miguel Franco (JM)
Ana Belén Mecina (AB)
Josep Tost (J)
Marta Berenguer (M)
Ruxandra Donea (R)
Susana Sánchez Ramón (SS)
Virginia Carbajosa Rodríguez (VC)
Pascual Piñera (P)
José Andrés Sánchez Nicolás (JAS)
Raquel Torres Garate (RT)
Aitor Alquézar-Arbé (A)
Miguel Alberto Rizzi (MA)
Sergio Herrera (S)
Javier Jacob (J)
Alex Roset (A)
Irene Cabello (I)
Antonio Haro (A)
Fernando Richard (F)
José María Álvarez Pérez (JMÁ)
María Pilar López Diez (MPL)
Pablo Herrero Puente (PH)
Joaquín Vázquez Álvarez (JV)
Belén Prieto García (BP)
María García García (MG)
Marta Sánchez González (MS)
Pere Llorens (P)
Patricia Javaloyes (P)
Víctor Marquina (V)
Inmaculada Jiménez (I)
Néstor Hernández (N)
Benjamín Brouzet (B)
Begoña Espinosa (B)
Juan Antonio Andueza (JA)
Rodolfo Romero (R)
Martín Ruíz (M)
Roberto Calvache (R)
María Teresa Lorca Serralta (MTL)
Luis Ernesto Calderón Jave (LEC)
Beatriz Amores Arriaga (BA)
Beatriz Sierra Bergua (BS)
Enrique Martín Mojarro (EM)
Brigitte Silvana Alarcón Jiménez (BSA)
LisetteTravería Bécquer (L)
Guillermo Burillo (G)
Lluís Llauger García (LL)
Gerard Corominas LaSalle (GC)
Carmen Agüera Urbano (CA)
Ana Belén García Soto (ABG)
Elisa Delgado Padial (ED)
Ester Soy Ferrer (ES)
José Manuel Garrido (JM)
Francisco Javier Lucas-Imbernón (FJ)
Rut Gaya (R)
Carlos Bibiano (C)
María Mir (M)
Beatriz Rodríguez (B)
José Luis Carballo (JL)
Esther Rodríguez-Adrada (E)
Belén Rodríguez Miranda (BR)

Auteurs

Xavier Rossello (X)

Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain.
Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares (CIBERCV), Spain.

Víctor Gil (V)

Emergency Department, Hospital Clínic Barcelona, Spain.

Rosa Escoda (R)

Emergency Department, Hospital Clínic Barcelona, Spain.

Javier Jacob (J)

Emergency Department, Hospital Universitari de Bellvitge, Spain.

Alfons Aguirre (A)

Emergency Department, Hospital del Mar, Spain.

Francisco J Martín-Sánchez (FJ)

Translational Laboratory for Cardiovascular Imaging and Therapy, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Spain.
Emergency Department, Hospital Clínico San Carlos, Spain.

Pere Llorens (P)

Emergency Department, Hospital General de Alicante, Spain.

Pablo Herrero Puente (P)

Emergency Department, Hospital Universitario Central de Asturias, Spain.

Miguel Rizzi (M)

Emergency Department, Hospital de la Santa Creu i Sant Pau, Spain.

Sergio Raposeiras-Roubín (S)

Department of Cardiology, University Hospital Álvaro Cunqueiro, Spain.

Desiree Wussler (D)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Switzerland.

Christian E Müller (CE)

Department of Cardiology, Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Switzerland.
The GREAT (Global REsearch in Acute cardiovascular conditions Team) network.

Etienne Gayat (E)

Department of Anesthesiology and Critical Care Medicine, Saint Louis Lariboisière University Hospital, France.

Alexandre Mebazaa (A)

The GREAT (Global REsearch in Acute cardiovascular conditions Team) network.
Department of Anesthesiology and Critical Care Medicine, Saint Louis Lariboisière University Hospital, France.

Òscar Miró (Ò)

Emergency Department, Hospital Clínic Barcelona, Spain.
The GREAT (Global REsearch in Acute cardiovascular conditions Team) network.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH